


WW WW Holding
(8442 TT)
Nov. 2024



Disclaimer



- The information contained in this confidential document ("Presentation") has been prepared by WW Holding (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

KEY POINTS



20Y↑

Experience in
manufacturing

NT\$6.3↑

YTD Revenue

8,600

Employees
globally

155↑

Production
Lines

7

Production
Sites

80↑

Global Brands

8442

Stock Code on Taiwan
Stock Exchange



COMPANY OVERVIEW



MILESTONES



1998-2006 Founded/ Structuring



1998 - Formerly Honour Rich Ltd., Wilson Group Holdings Ltd. was founded in Dongguan, Guangdong, China, and has been engaged in high-end boutique bags since 1998.

2003 – Nike on Board

2004 – Established Dongguan Wellpower Sporting Goods for sports protective gear and accessories.

2006 – Established a new site in Huaian, Jiangsu.

2006-2017 Corporate Expansion



- **2006 – Kipling、Tumi、Decathlon on Board**
- **2008-09 – Under Armour and JR286 on Board**
- **2011-13** – Nike: Best Stable Supplier Award, Best Innovative Product Award, Best Supplier Award.
- **2013-15** – JR286: Best Product Quality Award, Best Supplier Award.
- **2014 – Longchamp on Board**
- **2014** – Renamed the company to WW Holding Inc.
- **2014** – Merged with Wilson Group Holdings Limited.
- **2016 – Armani and Hugo Boss on Board**
- **2016 – IPO in Taiwan TAIEX (8442 TT)**

2015 - 2020 Sites Adjustment


- **2016- Established Wilson Leather (Thailand) Co.**
- **2016-17** – Expanding into South East Asia. **2017** – Established Global Worth Investment Holding and Global Vibrant Trading Limited as the holding arm for our luggage business.
- **2017 – Acquired TWT** – a major supplier to Tumi bags and luggage.
- **2020-Acquired Vietnam Virtue King** main supplier of NIKE sports bags.

2021 - Beyond Strengthen Leadership

**Improve Efficiency
Diversify Sites
Expand Client Base
Nurture Sustainability**




HOLDING STRUCTURE



PRODUCTS



Protective Gears



Sports Gloves



Sports Accessories



Sports bags/Golf bags



Nylon Luxury Bags



Leather Luxury Bags



Luggage & Suitcases



PRODUCTION SITES



Thailand



- Business bags, luggage
- Lines : 11
- Staff : 1,282

Xingguo, Jianxi



- Sporting goods
- Lines : 28
- Staff : 618

Dongguan, Guangdong



- Development Center
- Luxury bags, sports bags
- Lines : 23
- Staff : 1,842

Phnom Penh, Cambodia



- Luxury bags, sports bags
- Lines : 46
- Staff : 2,964

Bavet, Cambodia



- Sporting goods
- Lines : 12
- Staff : 306

Pinyang, Vietnam



- Sports bags, golf bags
- Lines : 35
- Staff : 1,615

Taiwan





- Taipei HQ
- Taichung Technique Center

8,309 Employees
148 Production Lines
2 Business Group

* By Sept 2024

EXPANSION IN CAMBODIA COMPLETED BY DEC. 24




DEVELOPMENT AROUND WELLPPOWER CAMBODIA SITE



- 01 Land price in surrounding area**
Both sides of 317B Highway from \$5 to now 20\$/50\$/sq. meter
- 02 Jin-Ba Freeway**
2023/6 began.
To complete by 2027/12
15km from WP
- 03 Jin-Ba HSR**
2024 begins.
To complete by 2030
10km from WP
- 04 Interchange Comm. Zone**
2024 begins
To complete by 2030
10km from WP
- 05 New Port Check Point**
2028 begins
15km from WP
- 06 WP Temp. Site**
20km from New Site
18km from Bavet Check Point

The high-speed railway and highway connecting Vietnam will traverse Bavet City, and the Cambodian government is committed to the robust development of Bavet City

REVENUE CONTRIBUTION BY REGION




9M24	2023
39%	41%

	9M24	2023
Cambodia	23.18%	16.00%
Thailand	12.62%	19.00%
Vietnam	24.97%	24.00%
Total	60.77%	59.00%

主要客戶




CONTRIBUTION BY PRODUCTS



ANCIAL FORMANCE




9M24 FINANCIAL RESULTS-MARGINS GWTH



MONTHLY REVENUE



	2024	2023	2022	2021
JAN	717,294	488,235	628,299	436,365
Feb	500,251	654,583	502,452	331,062
Mar	592,625	575,638	582,559	400,487
Apr	764,106	717,925	727,512	442,003
May	762,768	700,798	827,982	478,925
Jun	713,521	781,922	826,501	493,224
Jul	820,005	707,631	772,258	499,506
Aug	760,142	729,781	742,442	361,070
Sep	684,937	669,263	813,844	402,938
Oct	707,906	640,328	775,033	430,275
Nov		641,587	712,442	560,352
Dec		637,342	659,816	563,944
TOTAL	7,023,555	7,945,033	8,567,530	5,400,151



YOY 4.76% YOY -7.27% YOY +59% YOY +44%

單位:新台幣千元

季毛利率與季純益率趨勢



資產負債表



NT\$m	2021	2022	2023	9H2023	9H2024	YoY (%)		
						2022	2023	9H2024
資產總額	5,026	6,608	6,170	6,135	6,771	31.5	(6.6)	10.4
現金	518	1,027	1,191	938	1,172	98.3	16	24.9
應收帳款&應收票據	1,493	2,028	1,769	1,842	2,001	35.8	(12.8)	8.6
存貨	1,048	1,163	920	968	1,110	11	(20.9)	14.7
固定資產	802	822	841	803	1,046	2.5	2.3	30.3
負債總額	3,342	4,232	2,985	3,430	3,178	26.6	(29.5)	(7.3)
應付帳款&應付票據	943	944	688	801	922	0.1	(27.1)	15.1
權益總計	1,684	2,377	3,185	2,705	3,594	41.2	34	32.9
重要財務比率 (%)								
應收帳款天數	73.1	75.3	87.5	92.1	83.4			
存貨週轉天數	67.9	59.8	60.2	62.8	57.2			
應付帳款周轉天數	51.0	51.0	47.2	51.8	47.4			
現金循環週期	90.0	84.1	100.5	103.1	93.2			
ROE (%)	4.5	31.3	22.1	26.4	24.0			
ROA (%)	1.7	10.9	10.9	11.4	12.4			
淨負債(現金)/股權 %	43.2	14.4	(22.8)	1.8	(19.3)			

綜合損益表




NT\$m	2021	2022	2023	9H2023	9H2024	YoY (%)		
						2022	2023	2024Q3
營業收入	5,400	8,539	7,921	6,023	6,311	58.1	(7.2)	4.8
營業成本	4,627	6,752	6,313	4,813	4,974	45.9	(6.5)	3.3
營業毛利	773	1,786	1,608	1,210	1,337	131.0	(10.0)	10.5
營業費用	(699)	(1,094)	(931)	(727)	(759)	56.5	(14.9)	4.4
營業利益	73	692	677	483	578	847.9	(2.2)	19.7
營業外收入及支出	11	11	(47)	4	30	-	(527.3)	650.0
稅前淨利	84	704	630	487	608	738.1	(10.5)	24.8
所得稅費用	(9)	(67)	(13)	3	(42)	644.4	(80.6)	(1500.0)
淨利歸屬於母公司業主	75	636	617	490	566	748.0	(3.0)	15.5
每股盈餘 (NT\$)	1.25	10.61	10.07	8.07	8.47	748.8	(5.1)	5.0
重要財務比率 (%)								
毛利率	14.4	20.9	20.3	20.1	21.2			
營業費用率	12.9	12.8	11.8	12.1	12.0			
營業利益率	1.4	8.1	8.5	8.0	9.2			
稅率	11.0	9.6	2.1	(0.6)	6.9			
淨利率	1.4	7.5	7.8	8.1	9.0			

股利發放和資本支出



(NT\$m)	2020	2021	2022	2023
淨利	(153)	75	636	617
現金股利	-	60	301	352
稀釋後每股現金股利(NT\$)	-	1	5	5.3
現金股利發放率	-	80%	47%	57%
現金股利殖利率	-	1.7%	6.06%	4.6%
資本支出	65	114	179	188
資本支出/營收	1.7%	2.11%	2.1%	2.4%


2024 營運展望




2025年營運展望



新廠區擴展



新客戶開發



AI新技術導入


2025年營運展望



新廠區擴展



新客戶開發




AI新技術導入

2025年營運展望



新廠區擴展



新客戶開發



AI新技術導入

新任營運長介紹-洪維謙



Wei-Chien (Wayne) Hung · 1st
Bioprocess Engineer | Team lead | Corporate Faculty | Yale Genomics
| Johns Hopkins University | Chicago Booth EMBA 2025



芝加哥大學Booth 商學院
EMBA, 企業管理, 2023/6
月- 2025/6月



耶魯大學
博士後研究：基因工程



約翰霍普金斯大學
化學與生物分子工程博士
2009-2014



**約翰霍普金斯大學彭博
公衛學院**
MHS, 生化數學、生化資
訊、計算生物學
MHS2007-2009



密蘇里大學-哥倫比亞校區
生物化學, 學士 2002-2007

工作經歷:



武田製藥
資深工程師 II/經理

美國麻州, 2020年7月- 2024年

- 管理全球武田製藥跨功能團隊, 例如: 資訊科學, GMP, 製造, 分析開發, 製成開發。
- 開發最新製程科技技術
- 規劃下世代製程科技, 導入智慧工廠以強化生產流程, 以工業4.0為最終目標



BIOGEN
科學家 II
波士頓 劍橋, 美國麻州 2019-
2020年7月



AstraZeneca
罕見疾病單位
紐海芬, 美國康乃狄克州,
2017年7月-2019年4月



約翰霍普金斯大學
博士後學人
化學及生物分子工程部門,
2014年10月-2015年12月

能力優勢:

- 憑藉強大的生物化學背景, 得以顯著提升威宏控股的研究與開發能力。
- 擁有對工業製造流程的全面了解, 可協助公司推動自動化生產及智慧工廠。
- 致力於學習商業管理, 以充分準備負責整個集團的運營。



威宏控股股份有限公司(8442 TT)

謝謝!

www.ww-holding.com.tw